Living immunotherapies. Corporate Presentation

Size: px
Start display at page:

Download "Living immunotherapies. Corporate Presentation"

Transcription

1 Living immunotherapies Corporate Presentation MAY 2018

2 All of the information herein has been prepared by the Company solely for use in this presentation. The information contained in this presentation has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained herein. The information contained in this presentation should be considered in the context of the circumstances prevailing at that time and has not been, and will not be, updated to reflect material developments which may occur after the date of the presentation. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes. This presentation may contain certain forward-looking statements and forecasts which relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on the Company s business, financial condition and results of operations. The terms anticipates, assumes, believes, can, could, estimates, expects, forecasts, intends, may, might, plans, should, projects, will, would or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in a forward-looking statement or affect the extent to which a particular projection is realised. Factors that could cause these differences include, but are not limited to, implementation of the Company s strategy and its ability to further grow, risks associated with the development and/or approval of the Company s products candidates, ongoing clinical trials and expected trial results, technology changes and new products in the Company s potential market and industry, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors. While we always intend to express our best judgment when we make statements about what we believe will occur in the future, and although we base these statements on assumptions that we believe to be reasonable when made, these forward-looking statements are not a guarantee of our performance, and you should not place undue reliance on such statements. Forwardlooking statements are subject to many risks, uncertainties and other variable circumstances. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of our control and could cause our actual results to differ materially from those we thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. We do not undertake, and specifically decline, any obligation to update any such statements or to publicly announce the results of any revisions to any of such statements to reflect future events or developments. 2

3 Medigene at a glance 1 A global leader in T cell immunology 2 Growing clinical pipeline in multiple indications 3 High-throughput assays for antigen and TCR discovery 4 DC vaccines as first validation of cellular therapies 5 High-profile partnerships to drive near and long term value 6 Strong and experienced management team 3

4 Progress of immunotherapy pipeline PROJECT INDICATION (TARGET) PRECLINICAL PHASE I PHASE II DC vaccine Acute myeloid leukemia (WT-1 / PRAME ) TCR 1 (MDG1011) AML, MDS,MM (PRAME) TCR-IIT * Multiple myeloma (MAGE-A1) Start 2018e TCR 2 Undisclosed TABs T cell leukemias + new applications * Investigator-initiated trial (IIT) of a publicly funded collaboration between MDC, Charité and Medigene. Additional IITs utilizing Medigene s DC vaccine technology are ongoing at LMU Munich (Phase I/II in AML) and Oslo University Hospital (Phase II in prostate cancer) 4

5

6 Personalized cancer treatment with TCR-Ts 4 Patient 1 Thawing and reinfusion into patient Leukapheresis & T cell isolation TCR-T cell product 3 2 GMP: expansion, freezing and quality tests GMP: activation of T cells and transfer of TCR from TCR pipeline 6

7 PRAME is the target of Medigene s 1 st lead TCR PRAME (Preferentially Expressed Antigen of Melanoma) is a well described cancer-testis (CT) antigen Literature reports (in addition to in-house data) that PRAME expression is high in tumors but very scarce or absent in normal tissues Medigene s clinical trials indicate that using a PRAME DC vaccine is safe and well tolerated, confirming other vaccine trials targeting PRAME PRAME mrna is expressed in 9 out of 10 common nonhematological cancers (NCI): bladder, breast, colorectal, kidney, liver, lung (NSCLC & SCLC), prostate, thyroid and uterus 7

8 PRAME broadly expressed across tumors types Tumor expression patterns: Scale is given as RSEM. RSEM quantifies gene and isoform abundances from single-end or paired-end RNA-Seq data. 8

9 PRAME shows high safety profile Analysis by immunohistochemistry Normal tissue expression: only testis among 30 tissues at RNA and no expression in 43healthy tissues at protein levels Source: Indivumed GmbH, Germany 9

10 Phase I/II clinical trial of MDG1011 in myeloid and lymphoid malignancies Target: PRAME (Preferentially Expressed Antigen in Melanoma) PRAME is a well characterized tumor antigen overexpressed in multiple hematological and solid tumor indications The drug, MDG1011: T cells expressing a HLA-A*02:01-restricted T cell receptor (TCR) specific for PRAME Trial outline: Combined Phase I/II safety, feasibility and early efficacy clinical trial Disease indications for Phase I, all in advanced stages: acute myeloid leukemia (AML) myelodysplastic syndrome (MDS) multiple myeloma (MM) 2 of the 3 indications will be carried over into Phase II 10

11 MDG1011 clinical trial design Phase I Phase II Approx. 12 patients in up to 4 dose cohorts 3+3 dose escalation design, up to 4 cohorts Each indication needs to be represented in a cohort Dose ranges from 100,000 to 10,000,000 transduced T cells per kg body weight Progression between dose cohorts will be decided by an independent Data and Safety Monitoring Board (DSMB). Multi-center study at three sites (University of Regensburg, Würzburg and Erlangen, Germany) 40 treated + 40 control patients 2 of 3 indications to be carried into Phase II after a positive DSMB assessment and PEI/ethics committee vote 40 HLA-A*02:01 and PRAME positive patients to be treated with MDG1011 (20 per indication) Another 40 patients, PRAME positive but HLA-A*02:01 negative, serve as control groups (20 control patients per indication) 11

12 MDG1011 clinical trial endpoints Phase I: Primary endpoint: Safety (incidence, severity of adverse events (AEs) at 3 months, maximum tolerated dose (MTD) based on dose limiting toxicities up to 28 days) Feasibility (percent of patients receiving the planned dose) at 3 months Secondary endpoints: Safety (incidence, severity of AEs at 6 and 12 months) Overall response rate (ORR), duration of response (DoR), time to progression (TTP), progression-free survival (PFS), overall survival (OS), quality of life (QoL) and the correlation of PRAME expression with the antitumor response, measured at 3, 6 and 12 months Phase II: Co-primary endpoints: Safety (incidence, severity of AEs) at 3 months Efficacy (ORR) at 3 months Secondary endpoints: Safety (incidence, severity of AEs) at 6 and 12 months ORR at 6 and 12 months, DoR, TTP, PFS, OS, QoL and the correlation of PRAME expression with the antitumor response at 3, 6 and 12 months 12

13 13

14 Medigene s approach to DCs vaccines GM-CSF + IL-4 monocytes New generation maturation cocktail with TLR 7/8 agonist mdc IL-12 high IL-10 low 2 days 1 day New New generation 3-day polarized mature 3d-mDCs Optimized interleukin (IL) secretion pattern for innate and adaptive immunity Optimal phenotype and function Fast production in 3 days Use of defined antigens (i.e. C/T, neo-antigens) Capacity to activate complex CD4+ and CD8+ T cell responses Use of frozen cells with long shelf-life 14

15 Ongoing DC Phase II part of clinical trial in AML Target: WT-1 with or without PRAME WT-1 = Wilms tumor 1 PRAME = preferentially expressed antigen in melanoma Clinical product: Dendritic cells of AML patients presenting WT and PRAME antigens Clinical trial outline: AML patients in complete remission after chemotherapy, not eligible for allo-transplantation. Goal is to assess prevention of relapse Phase I/II: open-label, prospective, non-randomized trial Completed recruitment of 20 AML patients: 6 phase I + 14 phase II Continuous vaccination for 2 years or until progression/death Primary study objectives: feasibility and safety Secondary study objectives: overall survival (OS), progression free survival (PFS), control of minimal residual disease (MRD), time to progression (TTP), induction of immune responses Single center trial at Oslo University Hospital ClinicalTrials.gov Identifier: NCT

16 Recent DC vaccine data from AACR 2018 IIT study presented by Oslo University Hospital: Clinical data for DC vaccine in 20 prostate cancer patients Seventy-five percent of the patients remain without biochemical relapse with a mean observation time of 47.5 (range 29-82) months 5 of 20 patients received DCs generated with Medigene s proprietary maturation cocktail The 5 patients given the new type of DCs have not experienced PSA relapse Adjuvant dendritic cell vaccines in high-risk prostate cancer patients following radical surgery can reduce the incidence of biochemical relapse Data on the successful production of AML DC vaccine: 20 patients with a median age of 59 years (range years) were recruited Successful production runs of dendritic cells for vaccination were achieved for all 20 AML patients Aliquots prepared to deliver 5-10 million cells per vaccine dose An additional apheresis for a second production run in order to generate sufficient vaccine doses was needed for only 4 out of the 20 patients Feasible and robust production protocol for high numbers of mature, clinical grade DCs from heavily pretreated, post-remission AML patients 16

17 17

18 TCRs vs CARs HER2 CD19 Minor histocompatibility antigens Cancer-germline antigens Differentiation antigens Viral antigens Mesothelin CD38 Universal antigens Mutations CARs target only surface proteins: App. 30% of human proteome Limited to cell surface antigens, only tens of options Recognition is Major Histocompatibility Complex (MHC)-independent Higher risks of side effects TCRs target also intracellular proteins: App. 70% of human proteome Recognize intracellular targets, with many thousands of options (more addressable targets) Recognition is MHC-dependent (adds specificity) Lower risk for side effects if TCRs are natural, nonmutated structures TCRs offer more options, more power, more sensitivity and more control 18

19 TCR-based immunotherapies Essential steps for TCR-based immunotherapies Antigen / epitope selection Well suited for indication(s), both liquid and solid tumors Adequate tumor expression Safe for healthy tissues T cell receptor discovery Optimal affinity TCRs High TCR surface expression TCR transfer of multi-functionality (cytokines and cytotoxicity) Recipient T cell production Pre-selected starting recipient T cells Consistent product characteristics under GMP Expansion and persistence of T cells in patients Innovative clinical trials Safe & feasible pre-treatment and cell dosing Multiple indications compared at early stage Genetic control groups for comparison to SoC 19

20 Bioinformatic tools for antigen selection Tool Source Content Information gained regarding HESPERIA The Cancer Genome Atlas (TCGA) Expression Atlas Human Protein Atlas Seven combined databases Patient tumor mrna expression Cancer cell line and normal tissue mrna expression Cancer tissue protein expression Healthy tissue protein and mrna expression Indications: Expression comparisons in different cancers Frequencies: Frequency of expression in patients with selected indications Variations: Variations in levels of expression of antigens in healthy and cancer tissues Epitopes: Expression of epitopes in healthy tissues, identification of mismatched epitopes for safety assessments 20

21 In vitro tools confirm suitability of selected antigens Tool Purpose Nanostring assay of proteins and RNAs Sensitive detection of antigens in healthy and tumor tissues Immunohistochemistry Patterns of antigen expression in tumors and healthy tissues qrt-pcr Biosensors Quantitative assessment of antigen in patient tumor samples Expression of specific pmhc ligands on healthy and tumor tissues 21

22 TCR discovery process using healthy donors Antigen selection Healthy donors GM-CSF + IL-4 Monocytes Lymphocytes Cancer antigen (ivt-rna) Proprietary maturation cocktail Priming of T cells with mature DCs Enriched T cell repertoire Mature DCs Isolation of antigen specific T cell clones Sequencing and full characterization of TCRs Vector encoding selected TCR sequence (SIN-virus) 22

23 Using three approaches to gain optimal-affinity TCRs DCs with self-hla only DCs plus selected non-self HLA (Medigene s proprietary approach) Foreign antigen Self antigen Self antigen Foreign HLA as ivt-rna + autologous T cells + autologous T cells + autologous T cells Abundant T cell clones (self-hla + foreign ag) Rare T cell clones (self-hla + self ag) Abundant T cell clones (non-self HLA + self ag) T cell clones are sources of unique TCRs for further studies 23

24 Rapid and efficient TCR lead candidate identification Antigen selection Preparation Priming Expansion Selection Highest level of standardization and reproducibility Exemplified by output over 12 month timeframe: TCR leads from priming wells automatically screened screened clones characterized specific T cell clones 24

25 TRBV Robust recipient cell process established Patient-derived recipient cell population with desired characteristics Selected TCR vector TCR-expressing T cells + Specifically-enriched cell populations allowing expansion, persistence and multi-functionality Safe vector system SIN- RV (self-inactivating retrovirus) TCR sequence matched to patient HLA, antigen and indication CD8 High transduction efficiency Strong TCR expression 25

26 Poly-functional T cells identified simultaneously at single-cell level Multi-color Elispot assay replaces three different technologies to define five functional parameters Deep insight of T cell function at single-cell level Enormous savings of time and cost High-throughput application Individual colored dots represent single T cells producing one or more functional molecules (cytokines and killer proteins) 26

27 Steady progress in science-driven innovation Cutting-edge technologies assessed to improve functional properties of T cell immunotherapies: Enhancement of T cell effector function in situ (Cancer Research 77:3577, 2017) Recombinant T cells with improved efficacy in challenging solid tumor environments (Collaboration with Rxi Pharmaceuticals) Innovative approaches to improve safety of next generation T cell therapies under evaluation and development: Specific tracking tools for T cells during GMP manufacture and in patient samples Suicide safety switch Inducible TCRs 27

28 TCR candidate pipeline demonstrates power of platform Project Indications Target identification/ validation Target selected Priming and TCR seq determination TCR lead candidates selected Initial TCR characterization ( Assay tree ) Clinical TCR lead selected Non-clinical development Submission of CTA Phase 1 PRAME MAGE-A1* AML, MDS, MM MM, liver, lung not disclosed n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. Own and partnered projects n.d. n.d. n.d. * Investigator-initiated trial (IIT) of a publicly funded collaboration between MDC, Charité and Medigene 28

29 Value creation in TCR development TCR generation module TCR leads GMP production module TCRmodified T cells Clinical development program TCRbased therapies TCR discovery collaborations b b TCR development collaborations MAGE-A1 development in MM with academic partners TCR clinical stage partnerships Medigene s PRAME TCR study MDG1011 Unique discovery capabilities, immune monitoring platform cgmp process potentially of interest to other parties Proprietary TCR therapies 29

30

31 Financial guidance 2018 FY 2017 GUIDANCE 2018 Total revenue 11.4 m m R&D expenses 14.9 m m EBITDA loss 12.1 m m Cash usage 20.4 m m Liquide assets as of 31 Dec 2017 amounted to 51.7 m. Medigene has sufficient financial resources for beyond the planning horizon of two years No milestone payments or cash inflows are included from existing or future partnerships or transactions 31

32 Outlook 2018 MDG1011, Medigene s first TCR trial: Treatment of first patient Treatment of first dose cohorts DC trial in AML, Oslo: Presentation of preliminary data on certain aspects of the trial Final read-out in 2019 TCR IIT, Berlin: Clinical trial authorization Study start Progress in bluebird collaboration 32

33 Medigene AG Lochhamer Straße Planegg / Martinsried Germany T F investor@medigene.com Listed on Frankfurt Stock Exchange (MDG1, Prime Standard, TecDAX)

Living Immunotherapies. Corporate Presentation OCTOBER 2018

Living Immunotherapies. Corporate Presentation OCTOBER 2018 Living Immunotherapies Corporate Presentation OCTOBER 2018 All of the information herein has been prepared by the Company solely for use in this presentation. The information contained in this presentation

More information

ANNUAL REPORT 2017 PRESS & ANALYST CONFERENCE CALL MARTINSRIED, MARCH 22, 2018

ANNUAL REPORT 2017 PRESS & ANALYST CONFERENCE CALL MARTINSRIED, MARCH 22, 2018 ANNUAL REPORT 2017 PRESS & ANALYST CONFERENCE CALL MARTINSRIED, MARCH 22, 2018 Prof. Dolores J. Schendel, CEO/CSO Dr. Thomas Taapken, CFO Dr. Kai Pinkernell, SVP Clinical Affairs/CMO "Safe Harbor" Statement

More information

Living Immunotherapies. Corporate Presentation DECEMBER 2018

Living Immunotherapies. Corporate Presentation DECEMBER 2018 Living Immunotherapies Corporate Presentation DECEMBER 2018 All of the information herein has been prepared by the Company solely for use in this presentation. The information contained in this presentation

More information

Living Immunotherapies. Corporate Presentation JANUARY 2019

Living Immunotherapies. Corporate Presentation JANUARY 2019 Living Immunotherapies Corporate Presentation JANUARY 2019 G All of the information herein has been prepared by the Company solely for use in this presentation. The information contained in this presentation

More information

March Corporate Presentation

March Corporate Presentation March 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements

More information

Corporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers

Corporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain

More information

Corporate Presentation September Nasdaq: ADXS

Corporate Presentation September Nasdaq: ADXS Corporate Presentation September 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding the ability and

More information

Corporate Presentation October 2018 Nasdaq: ADXS

Corporate Presentation October 2018 Nasdaq: ADXS Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements

More information

ADAPTIMMUNE INVESTOR PRESENTATION. August 2016

ADAPTIMMUNE INVESTOR PRESENTATION. August 2016 ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),

More information

ZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015

ZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015 ZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015 1 Forward-looking Statements This presentation contains certain forward-looking information about ZIOPHARM

More information

NOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A. C5aR. NKp46 HALF-YEAR RESULTS. Tumor antigen KIR3DL2 CD39 MICA/B CD73 SEPTEMBER 18, 2017

NOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A. C5aR. NKp46 HALF-YEAR RESULTS. Tumor antigen KIR3DL2 CD39 MICA/B CD73 SEPTEMBER 18, 2017 NOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A NKp46 C5aR Tumor antigen HALF-YEAR RESULTS KIR3DL2 MICA/B CD73 CD39 SEPTEMBER 18, 2017 Page 2 FORWARD LOOKING STATEMENT This document has been prepared by

More information

Determined to realize a future in which people with cancer live longer and better than ever before

Determined to realize a future in which people with cancer live longer and better than ever before Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation

More information

9M RESULTS 2014 CONFERENCE CALL DR. MATTHIAS SCHROFF, CEO

9M RESULTS 2014 CONFERENCE CALL DR. MATTHIAS SCHROFF, CEO 9M RESULTS 2014 CONFERENCE CALL DR. MATTHIAS SCHROFF, CEO BERLIN, 13 NOVEMBER, 2014 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments,

More information

RXi Pharmaceuticals. Immuno-Oncology World Frontiers Conference. January 23, 2018 NASDAQ: RXII. Property of RXi Pharmaceuticals

RXi Pharmaceuticals. Immuno-Oncology World Frontiers Conference. January 23, 2018 NASDAQ: RXII. Property of RXi Pharmaceuticals RXi Pharmaceuticals Immuno-Oncology World Frontiers Conference January 23, 2018 NASDAQ: RXII Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private

More information

JEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018

JEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018 1 JEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many

More information

Pioneering vaccines that transform lives.

Pioneering vaccines that transform lives. Pioneering vaccines that transform lives. Immunomic Therapeutics, Inc. LAMP-Vax for General Oncology Presentation Outline 1. Immunomic Therapeutics: corporate overview 2. Unmet need in cancer immunotherapy

More information

PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM

PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM HEMATOLOGY ONCOLOGY PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM COMMITTED TO ADVANCING DRUG DEVELOPMENT IN ONCOLOGY $ MARKETPLACE COMPLEXITIES increasingly competitive marketplace and rising cost pressures

More information

Combining HS-110 and anti-pd-1 in NSCLC. September 1, 2015

Combining HS-110 and anti-pd-1 in NSCLC. September 1, 2015 Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking

More information

More cancer patients are being treated with immunotherapy, but

More cancer patients are being treated with immunotherapy, but Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH

More information

A Biopharmaceutical Company Focused on Controlled Immunotherapies and Point-of-Care Solutions

A Biopharmaceutical Company Focused on Controlled Immunotherapies and Point-of-Care Solutions A Biopharmaceutical Company Focused on Controlled Immunotherapies and Point-of-Care Solutions Second Quarter 2017 Company Update and Financial Results July 31, 2017 2 Forward-Looking Statements This presentation

More information

Myeloid Differentiation Observed, Including Induction of CD38 in 85% of Evaluable Patients

Myeloid Differentiation Observed, Including Induction of CD38 in 85% of Evaluable Patients December 10, 2017 Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 Showing Biological and Clinical Activity as Single Agent in Genomically Defined AML and MDS Patients Clinical

More information

Business Update & Financial Results for Q1 2018

Business Update & Financial Results for Q1 2018 Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma

More information

Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy

Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Company Overview, September 2018 Safe Harbor Statement This presentation contains forward-looking

More information

Transforming science into medicine

Transforming science into medicine Transforming science into medicine 2 Forward-looking statements This presentation contains forward-looking statements. These statements include words like may, expects, believes, plans, scheduled, and

More information

June IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)

June IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our

More information

Corporate Deck JP Morgan January 2019

Corporate Deck JP Morgan January 2019 Corporate Deck JP Morgan 2019 January 2019 Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),

More information

PATENCY-1 Top-Line Results

PATENCY-1 Top-Line Results PATENCY-1 Top-Line Results December 13, 2016 2016 Proteon Therapeutics, Inc. Cautionary Note Regarding Forward-Looking Statements This presentation contains statements that are, or may be deemed to be,

More information

Leading the Next Wave of Biotech Breakthroughs

Leading the Next Wave of Biotech Breakthroughs Leading the Next Wave of Biotech Breakthroughs Corporate Extensive corporate assets Platforms Pipeline Partnerships Building a sustainable global business Platform licenses represent a source of non-dilutive

More information

Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018

Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018 Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities

More information

Actinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting

Actinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting December 4, 2018 Actinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting - Key highlights include near universal engraftment

More information

DCVax Novel Personalized Immunotherapies for Solid Tumors

DCVax Novel Personalized Immunotherapies for Solid Tumors DCVax Novel Personalized Immunotherapies for Solid Tumors Phaciliate Immunotherapy World Forum January 26, 2016 Disclaimer Certain statements made in this presentation are forward-looking statements of

More information

BAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY

BAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY BAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY This presentation includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which

More information

Idera Pharmaceuticals

Idera Pharmaceuticals Idera Pharmaceuticals ILLUMINATE-204 Clinical Data Update December 2018 Forward Looking Statements and Other Important Cautions This presentation contains forward-looking statements within the meaning

More information

INTERIM RESULTS AS OF JUNE 30, 2014 CSE/OMX:BAVA, OTC:BVNRY

INTERIM RESULTS AS OF JUNE 30, 2014 CSE/OMX:BAVA, OTC:BVNRY INTERIM RESULTS AS OF JUNE 30, 2014 Q2 AUGUST 28, 2014 CSE/OMX:BAVA, OTC:BVNRY FINANCIAL HIGHLIGHTS 2.6 million doses IMVAMUNE delivered to the SNS during H1 (0.9 million in Q2) Increased contribution

More information

Anti-IL-33 (ANB020) Program

Anti-IL-33 (ANB020) Program Anti-IL-33 (ANB020) Program Phase 2a Peanut Allergy Clinical Trial Interim Data Update March 26 th 2018 NASDAQ: ANAB Safe Harbor Statement This presentation and the accompanying oral presentation contain

More information

MOLOGEN AG Jefferies 2014 London Healthcare Conference

MOLOGEN AG Jefferies 2014 London Healthcare Conference Jefferies 2014 London Healthcare Conference Dr. Matthias Schroff Chief Executive Officer London 20 November 2014 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring

More information

Company overview. Highlights for the 1 st quarter 2018 (January-March)

Company overview. Highlights for the 1 st quarter 2018 (January-March) Company overview Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. The company is a leader in the rapidly developing field of

More information

Determined to realize a future in which people with cancer live longer and better than ever before Q Conference Call

Determined to realize a future in which people with cancer live longer and better than ever before Q Conference Call Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation

More information

MOLOGEN AG. Our research for you. German Equity Forum November 2012

MOLOGEN AG. Our research for you. German Equity Forum November 2012 Our research for you. German Equity Forum 12-14 November 2012 Disclaimer Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as

More information

MOLOGEN AG. Pioneering Immune Therapy. Q1 Results 2014 Conference Call. Dr. Matthias Schroff, CEO

MOLOGEN AG. Pioneering Immune Therapy. Q1 Results 2014 Conference Call. Dr. Matthias Schroff, CEO Pioneering Immune Therapy Q1 Results 2014 Conference Call Dr. Matthias Schroff, CEO Berlin, 14 May 2014 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to

More information

NY-ESO SPEAR T-cells in Synovial Sarcoma

NY-ESO SPEAR T-cells in Synovial Sarcoma NY-ESO SPEAR T-cells in Synovial Sarcoma ASCO Update June 6, 2017 Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform

More information

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014 1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include

More information

Determined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019

Determined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019 Determined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019 Forward-looking statements disclosure This presentation contains

More information

Merck ASCO 2015 Investor Briefing

Merck ASCO 2015 Investor Briefing Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation

More information

Corporate Presentation November Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers

Corporate Presentation November Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Corporate Presentation November 2015 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary

More information

Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results

Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717 Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results SOUTH

More information

Five Prime Therapeutics, Inc. Corporate Overview

Five Prime Therapeutics, Inc. Corporate Overview Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities

More information

Leerink Immuno-Oncology Roundtable Conference

Leerink Immuno-Oncology Roundtable Conference Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private

More information

ArQule Jefferies Global Healthcare Conference June 2015

ArQule Jefferies Global Healthcare Conference June 2015 ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning

More information

IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics

IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking

More information

The Next Generation of Immunotherapy Platforms. 36 th Annual J.P. Morgan Healthcare Conference January 2018

The Next Generation of Immunotherapy Platforms. 36 th Annual J.P. Morgan Healthcare Conference January 2018 The Next Generation of Immunotherapy Platforms 36 th Annual J.P. Morgan Healthcare Conference January 2018 Forward-Looking Statements This presentation contains certain forward-looking information about

More information

Dawson James Conference

Dawson James Conference Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding

More information

GSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017

GSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017 GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 217 GSK pipeline Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics

More information

Iris Bigalke ISCT Europe 2015 Regional Meeting

Iris Bigalke ISCT Europe 2015 Regional Meeting Vaccination with a new generation of tumorspecific mrna loaded dendritic cells prolong progression free survival in patients with different types of malignancies Iris Bigalke 25.09.2015 ISCT Europe 2015

More information

AVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET

AVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)

More information

Third Quarter 2015 Earnings Call. November 9, 2015

Third Quarter 2015 Earnings Call. November 9, 2015 Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements

More information

DCVax Novel Personalized Immune Therapies For Solid Tumor Cancers. SMi 4 th Annual Cancer Vaccines Conference September 16, 2015

DCVax Novel Personalized Immune Therapies For Solid Tumor Cancers. SMi 4 th Annual Cancer Vaccines Conference September 16, 2015 DCVax Novel Personalized Immune Therapies For Solid Tumor Cancers SMi 4 th Annual Cancer Vaccines Conference September 16, 2015 Disclaimer Certain statements made in this presentation are forward-looking

More information

VeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End

VeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show

More information

NewLink Genetics Corporation

NewLink Genetics Corporation Cantor Fitzgerald 2018 Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK October 3, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking

More information

LION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology

LION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private

More information

Celyad s CAR-T NKR-2 Program. Conference Call Presentation Wednesday, December 7 th :00pm CET / 8:00am EST

Celyad s CAR-T NKR-2 Program. Conference Call Presentation Wednesday, December 7 th :00pm CET / 8:00am EST Celyad s CAR-T NKR-2 Program Conference Call Presentation Wednesday, December 7 th 2016 2:00pm CET / 8:00am EST Forward Looking Statements In addition to historical facts or statements of current condition,

More information

Third Quarter 2018 Financial Results. November 1, 2018

Third Quarter 2018 Financial Results. November 1, 2018 Third Quarter 2018 Financial Results November 1, 2018 Agios Conference Call Participants Prepared Remarks Introduction RENEE LECK, Associate Director, Investor Relations Business Highlights & 2018 Key

More information

MOLOGEN AG. Pioneering Immune Therapy. Annual Results Analysts Call March 25, 2014

MOLOGEN AG. Pioneering Immune Therapy. Annual Results Analysts Call March 25, 2014 Pioneering Immune Therapy Annual Results 2013 Analysts Call March 25, 2014 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments,

More information

Bobby W. Sandage, Jr., PhD President & Chief Executive Officer. Lazard Capital Markets 8 th Annual Healthcare Conference

Bobby W. Sandage, Jr., PhD President & Chief Executive Officer. Lazard Capital Markets 8 th Annual Healthcare Conference Bobby W. Sandage, Jr., PhD President & Chief Executive Officer Lazard Capital Markets 8 th Annual Healthcare Conference Statements in this presentation that are not descriptions of historical facts are

More information

THERAPEUTIC IMPLICATIONS OF PREPARING AND ADMINISTERING INNATE IMMUNE CELLS. 9:40 am to 10:10 pm Laurence Cooper

THERAPEUTIC IMPLICATIONS OF PREPARING AND ADMINISTERING INNATE IMMUNE CELLS. 9:40 am to 10:10 pm Laurence Cooper THERAPEUTIC IMPLICATIONS OF PREPARING AND ADMINISTERING INNATE IMMUNE CELLS 9:40 am to 10:10 pm Laurence Cooper ljncooper@ziopharm.com 05-16-2016 Forward-looking statements This presentation contains certain

More information

OncoSec Provides 2018 Business Outlook

OncoSec Provides 2018 Business Outlook January 3, 2018 OncoSec Provides 2018 Business Outlook Complete stage 1 enrollment of PISCES/KEYNOTE-695 clinical trial of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) Present preliminary

More information

Bank of America Merrill Lynch 2016 Health Care Conference

Bank of America Merrill Lynch 2016 Health Care Conference Bank of America Merrill Lynch 2016 Health Care Conference Dr. Steven Stein Chief Medical Officer David Gryska Chief Financial Officer May 11, 2016 Forward Looking Statements Except for the historical information

More information

Determined to realize a future in which people with cancer live longer and better than ever before

Determined to realize a future in which people with cancer live longer and better than ever before Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains

More information

Dicerna Pharmaceuticals Overview. Delivering RNAi-Based Breakthrough Therapies

Dicerna Pharmaceuticals Overview. Delivering RNAi-Based Breakthrough Therapies Pharmaceuticals Overview Delivering RNAi-Based Breakthrough Therapies Forward-Looking Statements This information may contain projections and other forward looking statements regarding future events, including

More information

Dynavax Corporate Presentation

Dynavax Corporate Presentation Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,

More information

July, ArQule, Inc.

July, ArQule, Inc. July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical

More information

Pfizer Presents Final Phase 2 Data on Investigational PARP Inhibitor Talazoparib in Patients with Germline BRCA-Positive Advanced Breast Cancer

Pfizer Presents Final Phase 2 Data on Investigational PARP Inhibitor Talazoparib in Patients with Germline BRCA-Positive Advanced Breast Cancer For immediate release June 3, 2017 Media Contact: Sally Beatty (212) 733-6566 Investor Contact: Ryan Crowe (212) 733-8160 Pfizer Presents Final Phase 2 Data on Investigational PARP Inhibitor Talazoparib

More information

Update on cell therapy using dendritic cells

Update on cell therapy using dendritic cells Update on cell therapy using dendritic cells Prof. dr. Evelien Smits UAntwerp, 24 March 2017 evelien.smits@uza.be Hallmarks of cancer (Hanahan and Weinberg, Cell 2000) Hanahan and Weinberg, 2000 Extra

More information

Idera Pharmaceuticals 36 th Annual J.P. Morgan Healthcare Conference Idera Pharmaceuticals

Idera Pharmaceuticals 36 th Annual J.P. Morgan Healthcare Conference Idera Pharmaceuticals Idera Pharmaceuticals 36 th Annual J.P. Morgan Healthcare Conference Forward Looking Statements and Other Important Cautions This presentation contains forward-looking statements within the meaning of

More information

3Q 2016 presentation

3Q 2016 presentation Arming the patient s immune system to fight cancer 3Q 2016 presentation 17 November 2016 Important notice and disclaimer This report contains certain forward-looking statements based on uncertainty, since

More information

INTERIM RESULTS AS OF MARCH 31, 2014 CSE/OMX:BAVA, OTC:BVNRY

INTERIM RESULTS AS OF MARCH 31, 2014 CSE/OMX:BAVA, OTC:BVNRY INTERIM RESULTS AS OF MARCH 31, 2014 Q1 MAY 14, 2014 CSE/OMX:BAVA, OTC:BVNRY FINANCIAL HIGHLIGHTS 1.7 million doses delivered to the SNS during Q1 Full year financial expectations maintained DKK million

More information

PSMA-617 License Transaction. October 2, 2017

PSMA-617 License Transaction. October 2, 2017 PSMA-617 License Transaction October 2, 2017 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending,

More information

Breakthrough Cancer Therapies: Directing the Immune System to Eliminate Tumor Cells. Corporate Presentation June 2015

Breakthrough Cancer Therapies: Directing the Immune System to Eliminate Tumor Cells. Corporate Presentation June 2015 Breakthrough Cancer Therapies: Directing the Immune System to Eliminate Tumor Cells Corporate Presentation June 2015 Forward-looking statements / safe harbor This presentation and the accompanying oral

More information

TARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018

TARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018 NASDAQ: IMGN TARGET A BETTER NOW Current as of January 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward looking statements based on management's current expectations. These statements

More information

ArQule CorporateUpdate

ArQule CorporateUpdate ArQule April 2015 1 ArQule CorporateUpdate Safe Harbor This presentation and other statements by ArQule may contain forwardlooking statements within the meaning of the Private Securities Litigation Reform

More information

37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE

37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE 37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as

More information

Merus. Corporate Presentation. November 15, 2018

Merus. Corporate Presentation. November 15, 2018 Merus Corporate Presentation November 15, 2018 Disclaimer This presentation (including any oral commentary that accompanies this presentation) contains forward-looking statements within the meaning of

More information

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President

More information

Genomic Health. Kim Popovits, Chairman, CEO and President

Genomic Health. Kim Popovits, Chairman, CEO and President Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and

More information

ASH POSTER: LYMRIT UPDATE

ASH POSTER: LYMRIT UPDATE ASH POSTER: LYMRIT 37-01 UPDATE DECEMBER 2018 EDUARDO BRAVO, CEO LISA ROJKJAER, MD, CMO Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway www.nordicnanovector.com IR contact: ir@nordicnanovector.com

More information

MERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018

MERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018 MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward

More information

Amicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018

Amicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018 Amicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018 Introduction 2 Safe Harbor This presentation contains "forward-looking statements"

More information

CORPORATE PRESENTATION

CORPORATE PRESENTATION CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

More information

Immuno-Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. February 24, 2016

Immuno-Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. February 24, 2016 Immuno-Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D February 24, 216 GSK Pipeline Oncology R&D strategy Focusing on 3 areas fundamental to oncology Cancer Epigenetics Long-Term Survival

More information

ICML BETALUTIN LYMRIT STUDY UPDATE JUNE 14 TH, 2017

ICML BETALUTIN LYMRIT STUDY UPDATE JUNE 14 TH, 2017 ICML 2017 - BETALUTIN LYMRIT 37-01 STUDY UPDATE JUNE 14 TH, 2017 Disclaimer This presentation may contain certain forward-looking statements and forecasts based on uncertainty, since they relate to events

More information

COMPANY PRESENTATION. January 2019

COMPANY PRESENTATION. January 2019 COMPANY PRESENTATION January 2019 1 FORWARD-LOOKING STATEMENT This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise

More information

A NEW FRONTIER IN IMMUNO-ONCOLOGY

A NEW FRONTIER IN IMMUNO-ONCOLOGY A NEW FRONTIER IN IMMUNO-ONCOLOGY Proactive One2One Forum London, March 8 th 2018 Dr Richard Goodfellow LSE: SCLP.L CLINICAL STAGE IMMUNO-ONCOLOGY COMPANY Scancell is developing innovative immunotherapies

More information

Cancer Vaccines and Cytokines. Elizabeth A. Mittendorf, MD, PhD Assistant Professor Department of Surgical Oncology

Cancer Vaccines and Cytokines. Elizabeth A. Mittendorf, MD, PhD Assistant Professor Department of Surgical Oncology Cancer Vaccines and Cytokines Elizabeth A. Mittendorf, MD, PhD Assistant Professor Department of Surgical Oncology Disclosures I serve as the PI on a phase III trial sponsored by Galena BioPharma investigating

More information

SAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018

SAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018 SAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018 SAFE HARBOR STATEMENT Savara Inc. ( Savara or the Company ) cautions you that statements in this presentation that are not a description of historical

More information

GSK Oncology R&D Update

GSK Oncology R&D Update GSK Oncology R&D Update Axel Hoos, MD Senior Vice President, Oncology R&D February 2019 Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements.

More information

Positioned for Growth

Positioned for Growth Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient This presentation

More information

Building a Fully Integrated Biopharmaceutical Company. June 2014

Building a Fully Integrated Biopharmaceutical Company. June 2014 Building a Fully Integrated Biopharmaceutical Company June 2014 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation

More information

Announce Expected Initiation of an Investigator-Initiated, Randomized, Phase 2, Multicenter Trial of Ficlatuzumab and Cetuximab in HNSCC in 2H 2017

Announce Expected Initiation of an Investigator-Initiated, Randomized, Phase 2, Multicenter Trial of Ficlatuzumab and Cetuximab in HNSCC in 2H 2017 AVEO Oncology and Biodesix Announce Results from Two Investigator-Sponsored Phase 1 Studies of HGF Targeted Antibody Ficlatuzumab at the 2017 ASCO Annual Meeting Announce Expected Initiation of an Investigator-Initiated,

More information

INTERIM RESULTS AS OF MARCH 31, 2018

INTERIM RESULTS AS OF MARCH 31, 2018 INTERIM RESULTS AS OF MARCH 31, 2018 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of

More information

David Zaccardelli, PharmD Chief Executive Officer. J.P. Morgan 37 th Annual Healthcare Conference January 8, 2019

David Zaccardelli, PharmD Chief Executive Officer. J.P. Morgan 37 th Annual Healthcare Conference January 8, 2019 David Zaccardelli, PharmD Chief Executive Officer J.P. Morgan 37 th Annual Healthcare Conference January 8, 2019 Disclaimer Certain information contained in this presentation relates to or is based on

More information